Health Catalyst Reports Q3 2026 Revenue of $56.3 Million
Revenue exceeded the high end of prior guidance. Net income was $40.5 million, or $0.53 per share, including a $65.9 million gain from the Vitalware sale; adjusted loss was $0.03 per share. Health Catalyst reaffirmed full-year revenue and Adjusted EBITDA guidance.
Health Catalyst reported third-quarter 2026 revenue of $56.3 million, exceeding the high end of its previous guidance. The company achieved a net income of $40.5 million, or $0.53 per share, largely driven by a $65.9 million gain from the sale of its Vitalware business on July 31, 2026. Adjusted for one-time items, the company reported a loss of $0.03 per share. Management reaffirmed its full-year 2026 revenue guidance of $246 million to $249 million and Adjusted EBITDA guidance of $18 million to $18.5 million.
The company noted that year-over-year revenue declines were primarily due to the Vitalware divestiture and migration challenges related to its platform transition.